مباشر

FierceBiotechTransforming neurodegenerative disease treatment FierceBiotechAdvances and Opportunities in Dual Chamber Injectables FierceBiotechAchieving Effective Manufacturing Scaleup for Clinical and Commercial Success FierceBiotechUtilizing AI to Facilitate Combination Product Development FierceBiotechEnsuring Sustainability Throughout Drug and Device Development FierceBiotechUsing Digital Technologies to Enhance Patient Experience and Better Manage Supply Chain Endpoints NewsCDER chief Høeg expected to leave FDA, according to source Clinical OMICsPPG-Derived Digital Biomarker Developed for Peripheral Artery Disease Detection Charles RiverCharles River Laboratories stock (US1591881009): recent earnings and outlook under the microscope - AD HOC NEWS Clinical OMICsAntibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine Cancer Clinical OMICsExchange Marketplace Launched to Help Stalled Cell and Gene Therapies Clinical OMICsSingle Psilocybin Dose Relieves Depression for Over Three Months

Clinical OMICs ١٥ مايو ٢٠٢٦

Antibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine Cancer

Researchers report encouraging tumor response and survival data for sacituzumab govitecan in recurrent uterine cancer, offering potential new hope for patients...

Researchers report encouraging tumor response and survival data for sacituzumab govitecan in recurrent uterine cancer, offering potential new hope for patients whose disease progressed after chemotherapy and immunotherapy. The post Antibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine Cancer appeared first on Inside Precision Medicine .